Review Article

Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson’s disease

Valerie Joers\textsuperscript{1,2}, Marina E Emborg\textsuperscript{1,2,3}

\textsuperscript{1}Preclinical Parkinson’s Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison, 1220 Capitol Court, Madison, WI 53715, USA; \textsuperscript{2}Neuroscience Training Program, University of Wisconsin-Madison, Madison, WI 53715, USA; \textsuperscript{3}Department of Medical Physics, 1111 Highland Avenue, University of Wisconsin-Madison, Madison WI 53705, USA

Received December 18, 2013; Accepted February 2, 2014; Epub March 20, 2014; Published March 30, 2014

Abstract: Parkinson’s disease (PD) is currently recognized as a multisystem disorder affecting several components of the central and peripheral nervous system. This new understanding of PD helps explain the complexity of the patients’ symptoms while challenges researchers to identify new diagnostic and therapeutic strategies. Cardiac neurodegeneration and dysautonomia affect PD patients and are associated with orthostatic hypotension, fatigue, and abnormal control of electrical heart activity. They can seriously impact daily life of PD patients, as these symptoms do not respond to classical anti-parkinsonian medications and can be worsened by them. New diagnostic tools and therapies aiming to prevent cardiac neurodegeneration and dysautonomia are needed. In this manuscript we critically review the relationship between the cardiovascular and nervous system in normal and PD conditions, current animal models of cardiac dysautonomia and the application of molecular imaging methods to visualize cardiac neurodegeneration. Our goal is to highlight current progress in the development of tools to understand cardiac neurodegeneration and dysautonomia and monitor the effects of novel therapies aiming for global neuroprotection.

Keywords: Positron emission tomography, SPECT, \textsuperscript{18}F-FDA, \textsuperscript{11}C-MHED, cardiac dysautonomia, sympathetic nervous system, Parkinson’s disease

Introduction

Parkinson’s disease (PD) is classically described as a movement disorder associated to the loss of dopaminergic neurons in the substantia nigra pars compacta [1]. Yet today, PD is recognized as a multisystem disorder affecting several components of the central and peripheral nervous system [2]. This new understanding of PD helps explain the complexity of the patients’ symptoms while challenges researchers to identify new diagnostic and therapeutic strategies.

Abnormal autonomic control of the heart or cardiac dysautonomia [3-6], and cardiac sympathetic neurodegeneration are frequently observed in PD patients, although until recently frequently under diagnosed and mistreated. Presently PD treatments focus on replacing nigral DA loss, which do not help nonmotor symptoms and, in the case of cardiac dysautonomia worsen them [7, 8]. Therapies aiming to prevent or slow down central or peripheral neuronal loss are not currently available.

Central and peripheral neurodegeneration in PD has been linked to multiple pathogenic factors including alterations in mitochondrial bioenergetics, calcium homeostasis, toxic catecholaldehyde formation, accumulation of misfolded α-synuclein and other proteins (Lewy bodies) and neuroinflammation [9, 10]. Animal models of cardiac dysautonomia present an opportunity to assess those neurodegenerative pathways, identify targets for disease-modifying strategies and develop unbiased methods of evaluation. In vivo imaging techniques are emerging as means to identify and study changes in cardiac innervation, and hold promise as biomarkers for diagnoses, disease progression and therapeutic efficacy.

In this manuscript we critically review the relationship between the cardiovascular and nervous system in normal and PD conditions, cur-
rent animal models of cardiac dysautonomia and the application of molecular imaging methods to visualize cardiac neurodegeneration. Our goal is to highlight current progress in the development of tools to understand cardiac neurodegeneration and dysautonomia and monitor the effects of novel therapies aiming for global neuroprotection.

The heart-nervous system connection

Optimal cardiac function depends on the integrity of the heart-nervous system connection. The heart is innervated by the autonomic nervous system (ANS), which is part of the peripheral nervous system that involuntarily regulates visceral function. The ANS is classically divided into two components, the sympathetic and parasympathetic system. The sympathetic nervous system is responsible for fight-or-flight responses while the parasympathetic nervous system controls the rest-and-digest activities. These systems function in opposition, but work together to maintain homeostasis. Sympathetic and parasympathetic neural divisions play a major role in the regulation of cardiac function [11].

Parasympathetic innervation of the heart generally has an inhibitory effect, slowing down the heart rate and delaying the transmission of the atrial excitation to the ventricles [12]. The parasympathetic fibers originate in the nucleus ambiguous and the dorsal motor nucleus of the vagus. They reach the heart as the vagus nerve, which exits the medulla oblongata, passing through the jugular foramen and projects to the epicardial neural plexus to unevenly innervate all areas of the heart with dense innervation in the sinoatrial and atrioventricular nodes. Parasympathetic efferent neurons release the neurotransmitter acetylcholine that activates muscarinic receptors in cardiomyocytes and cardiac vasculature [13, 14].

Cardiac sympathetic innervation accelerates heart rate and increases ventricular contractility. Fibers of the sympathetic preganglionic neurons travel down the intermediolateral column of the spinal cord from T1-T5 and synapse with neurons in the paravertebral sympathetic ganglia located in lower cervical and upper thoracic regions, referred to as superior, middle and inferior cervical ganglia, thoracic ganglia and stellate ganglion (comprised of the inferior cervical (C7) and first thoracic ganglia) [15]. Axons from the postganglionic neurons targeting the heart descend with the cardiopulmonary splanchnic nerves along the anterior surface of the trachea to pass through the cardiac plexus located in the superior mediastinum. From the cardiac plexus the sympathetic efferents travel to the heart, where they follow the greater coronary arteries and innervate the myocardium of the atria or ventricles either directly or through interneurons of surrounding cardiac ganglia. They release the neurotransmitter norepinephrine (NE) also known as noradrenaline.

Sympathetic cardiac imaging targets different molecules involved in NE metabolism for visualization (Figure 1). NE is synthesized from dopamine by dopamine-β-hydroxylase and packaged into type 2 vesicular monoamine transporters (VMAT2). Once NE is released into the presynaptic cleft it binds and activates α and β receptors in neighboring cardiac tissues, with β1 and β2 adrenergic receptors playing the major role in myocardial sympathetic control. NE can also be reuptaken into the presynaptic terminal by NE transporters (NET), referred to as uptake-1 or by surrounding non-neuronal cells or myocardium and termed uptake-2. The NE is reuptaken into the nerve terminal and repackaged into synaptic vesicles through vesicular monoamine transporters (VMAT2) or enzymatically degraded by monoamine oxidase (MAO) or catechol-O-methyl transferase (COMT) and released into the bloodstream [16].

Cardiac sympathetic receptors are also activated by circulating catecholamines, which are mainly produced by chromaffin cells of the adrenal medulla [17]. These cells are derived from the embryonic neural crest that migrated to create the sympathetic chain [18-20]. They secrete catecholamines directly into the bloodstream. The adrenal medulla is innervated by presynaptic sympathetic fibers that travel through the aorticorenal ganglion and directly synapse on the medulla. These fibers release acetylcholine that binds to local nicotinic receptors. Because the medulla is directly innervated by preganglionic fibers it has been referred to as a modified sympathetic ganglion. Generally, catecholamines (dopamine, NE and epinephrine) and their metabolites (dihydroxyphenylglycol (DHPG) and dihydroxyphenylacetic (DOPAC)) are measured in plasma to assess the health of the adrenals. It should be noted
Cardiac nerve imaging in Parkinson’s disease

Figure 1. Graphic Representation of radioligands cellular target for visualization of cardiac sympathetic innervation. Norepinephrine (NE) is produced from dopamine by dopamine-β-hydroxylase (DbH) in neurosecretory vesicles of catecholaminergic neurons. After NE is released into the synaptic cleft it can be taken up into the sympathetic nerve terminal by norepinephrine transporters (NET), bind α2 or β1 adrenergic receptors (AR), enter cardiomyocytes or escape into the bloodstream. Similar to NE reuptake, radiotracers including 123/125I-MIBG, 18F-FDA, and 11C-MHED can enter the sympathetic terminal through NET (uptake-1). Once in the cardiac sympathetic nerve, NE and 18F-FDA are either metabolized by monoamine oxidase (MAO) into 3,4-dihydroxymandelic acid (DOMA)/metabolites or, like 123/125I-MIBG and MHED, packaged into synaptic vesicles entering through vesicular monoamine transporter 2 (VMAT2). Once the nerve is activated, NE and radiotracers that are not broken down by DbH (such as 18F-FDA) are released by exocytosis into the cleft. Alternatively, the radiotracers 123/125I-MIBG, 18F-FDA and 11C-MHED can be taken up (uptake-2) by non-neuronal cells, such as cardiomyocytes. Within these cells, NE and 18F-FDA can be metabolized by COMT. 99mTc-FBPBAT binds β1AR to activate the post-synaptic myocardial cell.

Figure 1. Graphic Representation of radioligands cellular target for visualization of cardiac sympathetic innervation. Norepinephrine (NE) is produced from dopamine by dopamine-β-hydroxylase (DbH) in neurosecretory vesicles of catecholaminergic neurons. After NE is released into the synaptic cleft it can be taken up into the sympathetic nerve terminal by norepinephrine transporters (NET), bind α2 or β1 adrenergic receptors (AR), enter cardiomyocytes or escape into the bloodstream. Similar to NE reuptake, radiotracers including 123/125I-MIBG, 18F-FDA, and 11C-MHED can enter the sympathetic terminal through NET (uptake-1). Once in the cardiac sympathetic nerve, NE and 18F-FDA are either metabolized by monoamine oxidase (MAO) into 3,4-dihydroxymandelic acid (DOMA)/metabolites or, like 123/125I-MIBG and MHED, packaged into synaptic vesicles entering through vesicular monoamine transporter 2 (VMAT2). Once the nerve is activated, NE and radiotracers that are not broken down by DbH (such as 18F-FDA) are released by exocytosis into the cleft. Alternatively, the radiotracers 123/125I-MIBG, 18F-FDA and 11C-MHED can be taken up (uptake-2) by non-neuronal cells, such as cardiomyocytes. Within these cells, NE and 18F-FDA can be metabolized by COMT. 99mTc-FBPBAT binds β1AR to activate the post-synaptic myocardial cell.

Orthostatic hypotension (OH) is defined as a drop in systolic and diastolic blood pressure of more than 20 and 10 mm Hg, respectively, after a 3-5 minute postural challenge from a supine position [25, 26]. OH has been reported to occur in up to 58% of PD patients [27, 28], though up to 38.5% were found asymptomatic [29]. In general, postural challenge of this nature can lead to symptoms as subtle as fatigue, weakness, impaired cognitive performance, neck and back pain or as disabling as control of the heart or cardiac dysautonomia [21]. Interestingly, PD patients present with varying levels of cardiac denervation and may not have measureable autonomic abnormalities [22]. This could be related to the sensitivity of the tools used to identify sympathetic loss vs. dysautonomia or to individual thresholds of neurodegeneration needed before symptoms can be detectable. Although cardiac neurodegeneration and dysautonomia in PD are intimately related, different symptoms have been linked to each component. Cardiac neurodegeneration in PD presents with orthostatic hypotension, fatigue, dysrhythmias, shortness of breath during exercise, and reduced time to peak heart rate [3-6]. Other more lethal consequences of cardiac denervation, such as arrhythmias, are not frequent causes of death in PD. Cardiac dysautonomia refers to the symptoms associated not only to cardiac nerve loss but also to the decline in circulating catecholamines. Specifically, cardiac dysautonomia symptoms reported in PD also include OH and fatigue, plus increased corrected QT intervals, reductions in heart rate variability and plasma NE [23, 24]. Below we describe the main physiological manifestations of cardiac neurodegeneration and dysautonomia in PD (Table 1).

The relationship between symptoms of cardiac neurodegeneration and dysautonomia in PD

Cardiac sympathetic neurodegeneration refers to loss of catecholaminergic innervation to heart tissues, and has been proposed as an underlying mechanism of abnormal autonomic that concentration of plasma NE directly relate to cardiac performance.

Orthostatic hypotension (OH) is defined as a drop in systolic and diastolic blood pressure of more than 20 and 10 mm Hg, respectively, after a 3-5 minute postural challenge from a supine position [25, 26]. OH has been reported to occur in up to 58% of PD patients [27, 28], though up to 38.5% were found asymptomatic [29]. In general, postural challenge of this nature can lead to symptoms as subtle as fatigue, weakness, impaired cognitive performance, neck and back pain or as disabling as
Cardiac nerve imaging in Parkinson’s disease

Table 1. Differential diagnosis of cardiac dysautonomia symptoms in Parkinson’s disease (PD), multiple system atrophy (MSA), pure autonomic failure (PAF) and diabetes. Frequency and severity of cardiac dysautonomia symptoms vary by disorder

<table>
<thead>
<tr>
<th>Feature</th>
<th>PD</th>
<th>MSA</th>
<th>PAF</th>
<th>Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orthostatic hypotension</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Fatigue</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Increased QT interval</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Abnormal Valsalva Maneuver</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Circulating catecholamines do not double following supine position</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Basal low circulating catecholamines</td>
<td>x</td>
<td>-</td>
<td>x</td>
<td>-</td>
</tr>
<tr>
<td>Syncope</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>-</td>
</tr>
<tr>
<td>Denervation supersensitivity</td>
<td>x</td>
<td>-</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Decreased HRV</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Increased resting HR</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>x</td>
</tr>
<tr>
<td>Unresponsive HR to exercise, sleep (severe denervation)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>x</td>
</tr>
<tr>
<td>Postganglionic sympathetic neurodegeneration</td>
<td>x</td>
<td>-</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Preganglionic sympathetic neurodegeneration</td>
<td>-</td>
<td>x</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

HR, heart rate; HRV, heart rate variability.

dizziness, visual disturbances and syncope [30] which can increase risk of falls and greatly impair quality of life. Virtually all PD patients with OH present cardiac sympathetic denervation, yet of the remaining PD patients without OH, 50% also have cardiac denervation [31], suggesting that patients become symptomatic after surpassing a cardiac neurodegeneration threshold. Daily activities such as eating and exercise can exacerbate symptoms and some medications, including insulin, antihypertensives, tricyclic antidepressants and antiparkinsonian agents, can influence the prevalence or severity of OH [32]. OH can also be found due to non-neurogenic causes including low intravascular volume, reduced cardiac output, drug use, excessive vasodilatation, and cardiac impairment such as myocarditis [30, 33, 34].

Fatigue is present in over 40% of PD patients [35-37] and its presence correlates with cardiac dysautonomia and sympathetic denervation [38]. Central fatigue is found in many neurological disorders and encompasses both physical and mental features [39]. In a recent study [38], fatigued compared to non-fatigued PD patients (defined as a mean score higher than 3.3 on the Parkinson’s Fatigue Scale [40]), showed significantly more prevalence of cardiac denervation as detected by the sympathetic radiotracer $^{123}$I-metaiodobenzylguanidine and a trend of increased OH presence. Additionally, fatigued PD patients had significantly higher pressor responses to infusions of NE and dobutamine, a selective β1 stimulant, further confirming the loss of presynaptic sympathetic nerves and denervation supersensitivity [38]. Other studies have found a measureable relationship between fatigue and cardiac functioning as evaluated by stroke index and cardiac output index [41].

PD patients experience dysregulation in the electrical activity of the heart that can put them at risk to develop cardiac dysrhythmias. Prolongation in the corrected QT (QTC) interval, which describes ventricular depolarization and repolarization corrected for heart rate, predicts cardiovascular mortality and has been reported in PD [42, 43]. It is not clear how this measurement is a predictor of arrhythmias in PD, and further longitudinal studies must be completed to understand the correlation with cardiovascular causes of death [44]. Similar to other physiological cardiac autonomic measurements, QTC correlates with Hoehn & Yahr (H&Y) PD staging and duration of disease [42]. Furthermore, anti-parkinsonian drugs did not have adverse effects on QT intervals [42, 43], unlike other classes of drugs such as antiemetics, antidepressants and antibiotics [45].

Dysfunction in the electrical activity of the heart can also lead to changes in cardiac rhythmicity that is regulated by both sympathetic and parasympathetic mechanisms, referred to
as cardiovagal function. This balance can be evaluated by the R-R variation or heart rate variability (HRV), and although there are many methods to analyze HRV it is most widely measured with power spectral analysis for time and frequency domains. PD has been associated with a decrease in HRV that worsens with disease severity and further supports the involvement of the peripheral sympathetic system in PD [46-49]. Importantly, diminished HRV may have life threatening consequences; in myocardial infarction it is considered a strong predictor of mortality [50, 51]. Because of the association between HRV and cardiac denervation, HRV has been a suggestive measure of reinnervation [52-55].

Changes in cardiovagal function in PD can also be evaluated during the “Valsalva maneuver” in which the relationship between the interbeat interval and systolic blood pressure are analyzed after forceful exhalation against a closed airway. In PD, sympathetic cardiovascular responses are hampered following a decrease in stroke volume compared to controls, described by a drop in blood pressure during continued strain (phase II) and no overshoot after normal breathing (Phase IV) [4, 23, 56].

Decreased concentration of circulating plasma NE is another measure used to detect dysautonomia in PD, yet caution when analyzing the data is needed, as the patient’s condition during sample collection may affect the results. Multiple PD studies have confirmed that the level of plasma NE depends on the patient’s orthostatic response. At rest, reduced plasma NE has been reported in PD patients with OH compared to PD patients without OH [25, 57, 58]. However, other studies have shown no significant difference in NE concentrations at rest in PD with OH or even an increase in PD patients without OH compared to age-matched controls [25]. Normal levels of adrenaline and its metabolite metanephrine have been reported in PD patients at rest with OH and low NE, suggesting variability in adrenomedullary function [59]. Reduced plasma NE in PD patients has been linked to changes in the adrenal medulla, including decreased adrenal catecholamines and TH [60-62] and presence of Lewy body pathology [63].

Medications can affect the levels of plasma NE and should be controlled to accurately detect catecholamine production. For example, at rest PD patients with OH off-levodopa have been reported to have levels of plasma NE and DHPG lower than on-levodopa, while the latter had similar levels to healthy controls [64]. It should be noted that an earlier study from the same group found significantly decreased basal NE levels in PD with OH than without when excluding patients with high levels of levodopa [57].

Because of the variability found in plasma catecholamines at rest researchers have adopted to orthostatic increment measurements where patients stand for at least 5 minutes after being in a supine position for 15 minutes for blood sampling. Following the postural challenge, plasma NE increased more than 60% in 11 of the 18 PD patients lacking OH compared to 100% in controls, while PD with OH did not have similar increases to either group [57]. Controlling for antiparkinsonian treatments (e.g.: request off-levodopa overnight) is recommended for precise evaluations [64]).

**Modeling cardiac sympathetic neurodegeneration and dysautonomia**

Animal models of cardiac sympathetic neurodegeneration and dysautonomia are essential to study pathogenesis, validate therapeutic targets and assess novel imaging tools. Today there are several animal models available that present different advantages and disadvantages for preclinical evaluation (Table 2).

**Surgical sympathectomy**

Surgical sympathectomy models are created by total resection of unilateral or bilateral sympathetic stellate or upper thoracic ganglia, which produces partial cardiac denervation [65]. This procedure has been used clinically to manage congenital long QT syndrome [66, 67], primary hyperhidrosis [68], and reduce ventricular tachyarrhythmias in patients with myocardial infarcts and ischemic or nonischemic cardiomyopathy [69, 70]. Surgical sympathectomy has been tested in animals including rats [71, 72], dogs [73, 74] and sheep [75] with different degrees of success. While surgical sympathectomy has the advantage of producing an immediate effect, it can be technically challenging, as it requires extensive and invasive surgery. In addition, the regional innervation of the left ventricle by the right and left stellate ganglion...
Cardiac nerve imaging in Parkinson’s disease

is still unclear, and consequently the exact dispersion of denervation from a stellectomy is difficult to interpret. Another disadvantage is that spontaneous recovery is frequently observed after the procedure [76]. Functionally, electrocardiographic alterations were seen in dogs following unilateral stellate ganglionectomy including an increase in QT interval and prolonged refractory period [77]; and in humans, decreases in ejection fraction and resting and peak heart rates [78].

Streptozocin (STZ)

STZ is a glucosamine-nitrosourea compound that is used to model type I diabetes mellitus and its consequences, including metabolic cardiac nerve damage [79, 80]. STZ reaches into pancreatic β cells by glucose transport protein GLUT2, inducing cell death by DNA fragmentation, which can be perpetuated by STZ-induced reactive oxygen species and nitric oxide [81]. Its administration induces a diabetic-like state characterized by hyperglycemia, impaired glucose tolerance [82] and loss of β cell sensitivity. STZ concentrations, route of administration and exposure time vary depending on species (reviewed in [80]). Briefly, low dose intraperitoneal injections of STZ are more commonly used in rodents while intravenous administration is the preferred route for larger animals.

Cardiac effects of STZ (reviewed by [83]) have been observed in mice [84, 85], rats [86-90], monkeys [91], pigs [92] and dogs [93]. A number of studies have investigated the NE concentration in the heart [90, 94-96] and found significantly lower NE and β-adrenergic receptor levels with variation of loss across time between different STZ models. Yet, sympathetic ventricular denervation was confirmed by immunohistochemical staining where tyrosine hydroxylase was reduced in mice 6 months following STZ [97] and in rats 20 weeks after STZ [98]. STZ has produced functional effects such as decreased heart rate and HRV in rodents [96, 99-103]. Few STZ studies have shown an increase in heart rate [97, 104], which better matches the clinical presentation of tachycardia found in diabetic patients [105], but clashes with that found in denervated patients such as in PD. Together, this evidence suggests that the sympathetic activity of the heart can be affected in STZ models, and further character-

Table 2. Animal models of cardiac sympathetic denervation

<table>
<thead>
<tr>
<th>Model</th>
<th>Species</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical Sympathectomy</td>
<td>rat</td>
<td>Immediate effect</td>
<td>Invasive procedure</td>
</tr>
<tr>
<td></td>
<td>dog</td>
<td>Functional effects of sympathetic neurodegeneration</td>
<td>Denervation is not specific</td>
</tr>
<tr>
<td></td>
<td>sheep</td>
<td></td>
<td>Spontaneous recovery</td>
</tr>
<tr>
<td>Streptozocin (STZ)</td>
<td>mouse</td>
<td>Cardiac nerve damage confirmed by IHC</td>
<td>Model of hyperglycemia that produces other peripheral effects</td>
</tr>
<tr>
<td></td>
<td>rat</td>
<td>Functional effects of sympathetic neurodegeneration</td>
<td>Time course of cardiac NE loss and progression is variable</td>
</tr>
<tr>
<td></td>
<td>monkey</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>pig</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>dog</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rabbit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reserpine</td>
<td>mouse</td>
<td>Reversible effects</td>
<td>NE cell loss is questionable</td>
</tr>
<tr>
<td></td>
<td>rat</td>
<td>Repetitive doses has irreversible effect</td>
<td>Produce other peripheral and central effects</td>
</tr>
<tr>
<td></td>
<td>dog</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPTP</td>
<td>mouse</td>
<td>Potential to cause both central and peripheral catecholamine effects</td>
<td>High doses required for denervation</td>
</tr>
<tr>
<td></td>
<td>rat</td>
<td></td>
<td>Spontaneous recovery</td>
</tr>
<tr>
<td></td>
<td>monkey</td>
<td></td>
<td>Safety precautions needed for handling toxin and animals</td>
</tr>
<tr>
<td>6-OHDA</td>
<td>mouse</td>
<td>Sympathetic neurodegeneration confirmed by IHC</td>
<td>Intensive monitoring and care required during toxin delivery</td>
</tr>
<tr>
<td></td>
<td>rat</td>
<td>Decreases plasma catecholamines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>monkey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetic (Thy1α-Syn)</td>
<td>mouse</td>
<td>HRV and baroreflex abnormalities</td>
<td>Cardiac sympathetic innervation not yet evaluated</td>
</tr>
<tr>
<td></td>
<td>rat</td>
<td>Central and cardiac α-synuclein accumulations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rabbit</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>cat</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>dog</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>monkey</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NE, norepinephrine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA, 6-hydroxydopamine; IHC, immunohistochemistry; HRV, heart rate variability.
ization is needed to understand the extent of morphological and functional loss.

Other diabetic models with noradrenergic cardioneuropathy (reviewed by [83]) documented by molecular imaging are GK/Crj rats (a non-insulin dependent form; [106]), alloxaan-treated rabbits [98] and BioBreeding rats [107], yet a discussion about these models is beyond the scope of this review.

Reserpine

Reserpine is an alkaloid used in the past as an antipsychotic and antihypertensive treatment [108]. It irreversibly blocks active and passive NE uptake into storage vesicles by blocking VMAT2, thereby depleting the vesicular NE storage [109, 110]. Catecholamine depletion from a single dose of reserpine is temporary until VMAT2 can be replenished [111], but its repeated administration has a cumulative effect of profound and irreversible catecholamine loss [108].

The cardiac effects of reserpine have been tested in mice [112], rats [113], dogs [114] and rabbits [115]. In rats (4 mg/kg ip) a decline in endogenous catecholamines was found by 1 hour and a highest depletion at 4 hours, gradually increasing to baseline levels. In the heart, NE recovery was not seen until 15 days post reserpine dosing (4.5 mg/kg x 2). Directly after a single dose of reserpine, heart rate increases due to the release of NE from heart tissues, while after two daily doses (day 3 and 2 before analysis) increases in heart rate are not observed [114].

Reserpine also exerts its catecholamine depleting effects in the paraganglia [116], adrenal medulla [117-119], brain [120-122] and liver with the extent of loss and recovery subject to the dose, route of administration and blood flow to the organ [117]. The overall effect and time-course of recovery varies among tissues. For example, in order to achieve 25% reduction of catecholamines in the submaxillary gland, a dose had to be 2-10 times greater than the dose eliciting 25% loss in the heart. In a heart with 80-100% loss, there was 50% cardiac recovery after 7-15 days, while the superior cervical ganglia recovered almost completely after 7 days [123]. Reserpine’s side effects include sleepiness, diarrhea, impaired temperature regulation and hypersecretion of adrenocorticotropic hormone [108].

PD genetic models

PD patients with genetic mutations such as leucine-rich repeat kinase 2 (LRRK2) R1441G, T2356I and G2019S or triplication of the α-synuclein gene have cardiac neurodegeneration and dysautonomia [31, 124-127]. Rodent models based on genetic mutations linked to PD have been developed [128], yet most of the research has focused on their central dopaminergic cell neurodegeneration and subsequent motor disturbances. Exceptions are mice that overexpress wild-type α-synuclein under the Thy-1 promoter (Thy1α-Syn or Thy1-ASO). These mice have proteinase-K resistant accumulations of α-synuclein in ventricular and atrial walls [129], and increased HRV [130] and impaired baroreflex at an early age [131]. Molecular imaging studies for cardiac innervation have not been performed in these models; therefore, it is not clear if these mice exhibit cardiac neurodegeneration.

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

MPTP is a lipophilic neurotoxin, widely used to model PD nigral dopaminergic cell loss in mice [132-134] and monkeys [135, 136]. MPTP central effects are due to its capacity to cross the blood brain barrier, but it also has peripheral effects including loss of cardiac sympathetic innervation [6, 137-140].

MPTP active form, MPP⁺, is produced by monoamine oxidase (MAO) present in brain astrocytes and liver cells. MPP⁺ is preferentially taken up by nigral neurons through the dopamine transporter (DAT). Peripherally, it is thought that MPP⁺ selectively enters postganglionic sympathetic nerves through monoamine transporters [140, 141]. In either case, MPP⁺ concentrates in mitochondria where it inhibits complex I, leading to catecholamine neuron degeneration by affecting energy production and increasing oxidative stress [142-144]. Although, MAO-B inhibitors prevent nigral dopaminergic cell loss, they do not protect against cardiac NE loss, suggesting that MPTP does not need to be converted to MPP⁺ for cardiac effects and that other factors may be involved in MPTP toxicity in the heart [145]. Peripherally,
MPTP toxicity has selective effects in for catecholamine neurons in the heart and gut [146, 147], but spares the loss of chromaffin cells of the adrenal medulla, although catecholamine production is altered [148].

MPTP-induced cardiac sympathetic nerve loss has been demonstrated in mice [6, 140, 149, 150], rats [151], and monkeys [152]. Doses and regimens of intoxication vary between species to produce peripheral cardiac damage, yet the effects seem to be short term. Mice administered a single MPTP dose of 32 mg/kg ip had significantly decreased cardiac NE levels 24-48 hours after dosing, but returned to normal levels within 4-7 days [153]. In another study, rats were administered a daily dose of MPTP or MPP+ (20 mg/kg ip x 5 days) to produce 93.5-100% loss of cardiac NE compared to controls, and 10 days after the final MPTP/MPP+ dose, the cardiac NE levels had recovered to 40% loss [151]. Furthermore, immunohistochemical analysis 1 week after the administration of MPTP (30 mg/kg ip x 2) to mice revealed well preserved cardiac NE innervation, yet HPLC analysis resulted in decreased NE and dopamine heart content [154], suggesting functional cardiac sympathetic loss but not actual denervation. In monkeys systemic MPTP temporarily induced cardiac nerve loss as well as lower levels of circulating catecholamines [152].

6-Hydroxydopamine (6-OHDA)

6-OHDA is a neurotoxin widely used to model PD dopaminergic nigral cell loss in rodents by direct intracerebral delivery, as 6-OHDA does not cross the blood brain barrier [155]. 6-OHDA is also used to model cardiac sympathetic neurodegeneration by systemic dosing. Either in the central or peripheral nervous system, 6-OHDA enters the catecholaminergic neurons through monoamine transporters and induces sympathetic neuronal loss by increasing the production of reactive oxygen species (ROS), and disrupting energy metabolism and neuronal membranes [156]. It should be noted that a decrease in nocturnal heart rate has been described in rats given a unilateral injection of 6-OHDA into the medial forebrain bundle [157], but no other cardiac effects have been described after intracerebral 6-OHDA administration.

The effects of systemic 6-OHDA in sympathetic cardiac denervation have been evaluated in mice [158, 159], rats [160, 161], rabbits [162, 163], cats [164, 165], dogs [76, 166, 167] and monkeys [152, 168]. Dose and route of delivery of the neurotoxin vary between species. In general, 6-OHDA administration produces a strong sympathomimetic effect, as a result the method of preference is fractionated doses delivered slowly over a long period of time (hours) until an effective total dose is given. The 6-OHDA displacement of NE from its binding sites in sympathetic nerve terminals leads to an acute response including a marked rise in blood pressure, piloerection, mydriasis, and profuse salivation [76, 160]. Tachyphylaxis of the sympathetic response occurs during 6-OHDA dosing. Blood pressure increases are much less pronounced after a partial dose of 6-OHDA (approximately 10 mg/kg in dogs and monkeys), since the sympathetic nerve terminals are destroyed and no longer able to release NE. Within days following 6-OHDA, non-cardiovascular signs such as miosis, and diarrhea have been reported [76]. A cumulative dose of 50 mg/kg intravenously to dogs reduced NE cardiac apical content by 97% and basal content by 90% 5 days later, yet NE content increased in the stellate ganglia. Other studies have shown limited effect on the ganglia suggesting that 6-OHDA destroys the terminals of sympathetic postganglionic neurons without affecting the cell bodies [169, 170]. In rhesus monkeys 6-OHDA produces cardiac nerve loss that persists for up to 3 months and was associated with a decrease in circulating catecholamines compared to baseline [168].

In vivo visualization of cardiac sympathetic neurodegeneration in PD

The association between cardiac dysautonomia and sympathetic denervation has been established by correlating cardiac autonomic symptoms with cardiac sympathetic imaging. Both in animal models and patients, different molecular radiotracers have been designed to evaluate sympathetic functional integrity. Cardiac denervation, as determined by a reduction in radioligand uptake, has been confirmed postmortem in PD by markedly reduced immunohistochemical staining of tyrosine hydroxylase, neurofilament and S-100 protein in epicardial tissue [3, 5, 171]. The principal radiol-
Cardiac nerve imaging in Parkinson’s disease

The assessment of cardiac sympathetic innervation is crucial for understanding the progression of Parkinson’s disease. Various radiotracers are used for this purpose, including 123/125I-Meta-iodobenzylguanidine (123/125I-MIBG), 99mTc-4-fluorobenzyl-[4-(2-mercapto-2-methyl-4-aza-pentyl)-4-(2-mercapto-2-methylpropylamino)-piperidine][fluorobenzylpiperidinyl-bis-(aminoethanethiol)] (99mTc-FBPBAT), 6-18F-fluorodopamine (18F-FDA), and 11C-meta-hydroxyephedrine (11C-MHED; Figure 2). These radiotracers are detected using SPECT (Single Photon Emission Computed Tomography) imaging or PET (Positron Emission Tomography) imaging. A rotating gamma camera is used for SPECT imaging, while PET imaging requires the detection of gamma rays emitted from a radioisotope injected into the patient. This technique collects multiple 2D images that are reconstructed into a 3D structure. The compiled SPECT images have limited spatial resolution of 15 mm and increased occurrence of artifacts and noise. However, spatial resolution has been improved with technological advancements such as pinhole collimators [172]. The higher half-lives of SPECT agents allow patients to be observed for longer periods of time, lending a potential advantage to SPECT imaging. However, their half-lives also limit the number of follow-up studies that can be performed in the same day. SPECT analysis is traditionally regarded as non-quantitative, but recent developments are combining the technology with other modalities to enhance its diagnostic capabilities.
computed tomography to achieve quantitative image reconstruction [173]. Although SPECT cardiac imaging is more often used to evaluate myocardial perfusion and function for clinical management, it can also be used to detect cardiac neuronal architecture.

PET imaging differs from SPECT as it requires radionuclides that decay with positron emission creating two opposing photons that are coincidentally detected and processed to form an image corresponding to the concentration of radionuclide. PET radioisotopes generally have much lower half-lives than SPECT isotopes, and therefore must be synthesized near the PET scan facility. This can limit the use of PET scans since positron-emitting radionuclide production requires a cyclotron, which may not be easily available. To their advantage, PET isotopes result in lower radiation exposure to the patient and higher sensitivity, and do not limit the number of repeat tracer injections as SPECT. Spatial image resolution in clinical PET is as low as 3 mm full width at half maximum compared to 15 mm in SPECT for whole body scanning. Furthermore, attenuation correction is less challenging in PET analysis than in SPECT, minimizing artifacts [174]. Small animal PET scanners (microPET or Inveon) have very similar features as the clinical technologies, with the exception of improved detection efficiency to increase spatial resolution to 1-3 mm full width at half maximum [175].

\(^{123/125}\mathrm{I-MIBG}\)

MIBG is used to visualize cardiac sympathetic innervation in vivo and postmortem. MIBG acts as a false neurotransmitter (guanethidine) and is usually labeled with either \(^{123}\)-I for in vivo or \(^{125}\)I for ex vivo evaluation. It is taken up into presynaptic terminals through NET by uptake-1 mechanisms with 50% selectivity relative to uptake-2 into non-neuronal cells [176] (Figure 1). It is then distributed within the neuronal cytoplasm and stored in neurosecretory vesicles [177]. As \(^{123/125}\)I-MIBG is also taken up by non-neuronal cells through uptake-2 mechanisms, it has been argued that it does not provide a true measurement of neuronal integrity, although cardiac transplant patients, which lack sympathetic innervation, have no cardiac \(^{123/125}\)I-MIBG accumulation [178]. Unlike NE and other catecholamines, \(^{123/125}\)I-MIBG cannot be catabolized by MAO or COMT, which facilitates its effective visual detection. \(^{123}\)I-MIBG is easily purchased from a manufacturer. It is one of the most widely used clinical sympathoneuronal radiotracer.

\(^{123/125}\)I-MIBG is not positron-emitting therefore it is used as a SPECT radiotracer, although efforts are being made to develop a positron-emitting analogue. Heterogeneous \(^{123}\)I-MIBG uptake has been reported in the inferior wall of the left ventricle of normal subjects associated to physiological differences [179]. Further research must be completed to understand if the variation in the inferior wall is due to true physiological changes or due to attenuation or artifact correction methods that result in inaccurate assessments of regional distribution of sympathetic innervation [180]. \(^{123}\)I-MIBG is commonly analyzed by uptake and washout parameters, requiring early (15-20 minute) and delayed (2-4 hours) imaging. The routine semi-quantitative assessments for \(^{123}\)I-MIBG are the heart to mediastinum (H/M) ratio or washout rates. Both methods largely provide a global measure of sympathetic innervation and function; washout rates additionally provide information of catecholamine turnover.

**Clinical application of \(^{123}\)I-MIBG:** MIBG scintigraphy is used to aid in the differential diagnosis of PD, as H/M measurements are reduced in PD compared to multiple systems atrophy (MSA), progressive supranuclear palsy (PSP), vascular parkinsonism, essential tremor, and control patients (Table 3) [6, 181-184]. A recent meta-analysis report on \(^{123}\)I-MIBG scintigraphy determined that the delayed H/M had 89% sensitivity to detect PD and 77% specificity to differentiate PD from MSA [185] and 91.4% sensitivity and 78% specificity when discriminating between PD and PSP [186]. Yet, the relationship between cardiac \(^{123}\)I-MIBG and PD severity and duration is still not clear. Some studies have found that H/M measurements negatively correlate with PD stage, yet up to 55% of early stage PD patients already exhibit low \(^{123}\)I-MIBG measurements [6, 183]. Others have not found a clear association between H/M and PD stage or disease duration [184]. When evaluating central and cardiac cell loss, \(^{123}\)I-MIBG H/M from PD at all H&Y stages positively correlated with central dopamine loss in the striatum as detected by striatal uptake of N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-[\(^{123}\)I]iodophenyl) nortropane (\(^{123}\)I-FP-CIT), a
## Table 3. Comparison of clinical reports evaluating cardiac innervation in PD using $^{123}$I-MIBG

<p>| Reference          | Number of Patients | Mean PD age (age range) | PD H&amp;Y stage (disease duration yrs) | Methods to evaluate cardiac DYA | PD patient DYA description | Homogenous cardiac perfusion Y/N (radiotracer) | LV regions analyzed or uptake measurement | % of LV global uptake reduction | Region of maximal reduction (% of loss) | Significant loss of plasma catecholamines Y/N | Comments |
|--------------------|--------------------|-------------------------|-------------------------------------|---------------------------------|-----------------------------|-----------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------------------|----------|
| Braune et al., 1998| 10                 | - 8                     | No mean defined (60-83)             | Head tilt, OH evaluation after standing, plasma NE and Epi, valsalva | n=6 of 10 AF n=4 of 10 asymptomatic | Y ($^{99m}$Tc)MIBI (H/M ratio) | H/M ratio                       | N (NE reduced in 2 of 6 PD with AF at rest; majority have abnormal NE response after standing) | -                 | -                 | No correlation between DYA tests and plasma catecholamines or global MIBG uptake. |
| Orimo et al., 1999 | 46                 | 7 - 10                  | H&amp;Y 1, n=8; H&amp;Y 2, n=3; H&amp;Y 3, n=2; H&amp;Y 4, n=9; H&amp;Y 5, n=4 (disease duration not defined) | Head tilt, ECG (coefficient of variation RR interval) | n=13 of 46 OH with H&amp;Y &lt;3 | Y ($^{99m}$Tc)Thallium (H/M ratio) | 80-84% | -                 | -                 | -                 | H/M decreased with H&amp;Y stage progression. Duration of PD correlated with early H/M, but not with delayed. PD with OH had lower mean H/M than other PD. |
| Takatsu et al., 2000| 32                 | 5 - 7                   | H&amp;Y 1, n=2; H&amp;Y 2, n=9; H&amp;Y 3, n=1; H&amp;Y 4, n=6; H&amp;Y 5, n=1 (disease duration not defined) | OH evaluation after standing 24 hr, ambulatory and nocturnal BP monitoring | n=21 of 26 PD evaluated for DYA have OH and abnormal nocturnal BP | - | H/M ratio | 34.7-48.8% | - | - | Global MIBG normal in n=1 of 32 PD patients. Marked reduction found in H&amp;Y 1 and 2, but significant reduction at H&amp;Y 3-5. MIBG low in PD with or without DYA/abnormal BP. |
| Taki et al., 2000  | 41                 | 9 - 6                   | H&amp;Y 1, n=11; H&amp;Y 2, n=15; H&amp;Y 3, n=10; H&amp;Y 4, n=2 (disease duration not defined) | No additional cardiac DYA evaluation | n=0 of 41 AF, n=3 of 41 DB | Y ($^{99m}$Tc)MIBI and $^{99m}$Thallium (H/M ratio) | 28.1-38% | - | - | - | Global MIBG early and delayed H/M ratios significantly lower in PD than controls, MSA, and PSP. No significant differences in H/M between PD stages. |
| Courbon et al., 2003 | 18                 | 10 -                    | H&amp;Y 1, n=2; H&amp;Y 2, n=11; H&amp;Y 3, n=3 (3.6 non-DYA PD; 9.3 DYA PD) | OH evaluation after standing, ECG (BP and HR for RR interval), valsalva | n=10 of 18 PD with DYA and H&amp;Y &lt;2, n=8 of 18 PD non-DYA H&amp;Y &gt;3 | Y ($^{99m}$Tc)MIBI (H/M ratio, Anterior, inferior, lateral, septal walls and apex uptake assessed with a 3 pt color scale between PD and MSA. | 27.4% (non-DYA PD); 50.8% (DVA PD) | Apex (85%) in non-DYA, Infe-rior (70%) | - | - | H/M of PD with DYA significantly lower than non-DYA. |
| Orimo et al., 2005  | 5                  | - 3                    | Parkin: 70 (66-73); non-Parkin: 81 (70-91) | No stage defined (Parkin: 38-49; non-Parkin: 10-15) | - | - | - | 3.1-13.3% | - | - | Parkin have normal TH positive epicardial nerve fascicles. |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Patients</th>
<th>H&amp;Y/Stage</th>
<th>Evaluation</th>
<th>H/M Ratio</th>
<th>Overall PD</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spiegel et al., 2007</td>
<td>102</td>
<td>-</td>
<td>n=57; H&amp;Y 2, n=22; H&amp;Y 3 and 4, n=23 (disease duration not defined)</td>
<td>OH evaluation after standing (evaluated in n=19 H&amp;Y 1 and n=22 H&amp;Y 2-4)</td>
<td>n=6 of 19 H&amp;Y 1 and n=10 of 22 H&amp;Y 2-4 with OH</td>
<td>Y ($[^{99m Te}]$MIBI)</td>
<td>H/M ratio</td>
</tr>
<tr>
<td>Ruiz-Martinez et al., 2011</td>
<td>90</td>
<td>-</td>
<td>LRRK2: 70.3 (no range defined)</td>
<td>Mean LRRK2: 2.0, mean non-LRRK2: 2.1 (mean LRRK2: 9.2, mean non-LRRK2: 7.4)</td>
<td>-</td>
<td>-</td>
<td>H/M ratio</td>
</tr>
<tr>
<td>Chiara-valloti et al., 2012</td>
<td>37</td>
<td>-</td>
<td>H&amp;Y 1, n=15; H&amp;Y 1.5, n=8; H&amp;Y 2, n=7; H&amp;Y 3, n=7 (mean 26)</td>
<td>No additional cardiac DYA evaluation</td>
<td>-</td>
<td>-</td>
<td>H/M ratio</td>
</tr>
<tr>
<td>Tijero et al., 2013</td>
<td>25</td>
<td>-</td>
<td>LRRK2: 56.4, iPD: 59.2 (no range defined)</td>
<td>Stage not defined (mean LRRK2: 8.77, mean iPD: 6.47)</td>
<td>OH tilt test, Plas- ma NE, valsalva, deep breathing, autonomic question-naire</td>
<td>LRRK2, n=2 of 12 with OH; iPD, n=3 of 13 with OH</td>
<td>Y ($[^{99m Te}]$MIBI)</td>
</tr>
</tbody>
</table>

*H/M correlated with $[^{123}I]^M$MIBG uptake in the putamen ipsilateral to the prevalently effected side, but did not correlate with any other striatal uptake. | H/M correlated to BP response during valsalva phase IV in both iPD and LRRK2 groups. LRRK2 R1441G mutation had larger phase IV overshoot than G2019S (no other differences between mutations). |

Listed percentages describe loss of MIBG uptake compared to controls (unless otherwise noted) and reported originally in the reference (*) or calculated based on data (* numbers or * graph) from the publication, *compared to MSA group. $[^{[^{125/125}I-MIBG]}$, $[^{[^{123/125}I-Meta-iodobenzylguanidine]}$, AF, autonomic failure; BP, blood pressure; CBD, corticobasal degeneration; DYA, dysautonomia; Epi, epinephrine; H/M, heart to mediastium; H&Y, Hoehn & Yahr; HR, heart rate; LRRK2, leucine rich repeating kinase 2; LV, left ventricle; OH, orthostatic hypotension; MSA, multiple systems atrophy; NE, norepinephrine; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; UPDRS, unified Parkinson’s disease rating scale.
SPECT radiotracer taken up by DAT and therefore visualizing the density of dopaminergic neurons [187]. $^{123}$I-MIBG only correlated with $^{123}$I-FP-CIT uptake in the putamen on the most affected side but no other striatal nuclei, with $^{123}$I-MIBG accumulation reduced 14% [188]. These studies suggest that the effects on the central and peripheral systems are not uniform.

Regional instead of global $^{123}$I-MIBG cardiac analysis may be the key to identify progressive changes and possibly PD severity. Only one $^{123}$I-MIBG study reported a regional analysis, in which $^{123}$I-MIBG uptake was visually assessed at both the early and delayed images with a 3-point color scale in the anterior, inferior, lateral, septal and apical cardiac areas between nondysautonomia PD and MSA [182]. No differences were found between the 2 planar images and the largest $^{123}$I-MIBG reductions were noted in the inferior (70%) and apical (85%) regions of the left ventricle. The relationship between the regional uptake and any marker for PD severity (stage or duration) was not evaluated. Clearly, mapping a pattern of loss with $^{123}$I-MIBG is limited and further investigation is warranted.

To assess the relationship between cardiac denervation and abnormal cardiac symptoms, several studies combined $^{123}$I-MIBG imaging and autonomic tests including head tilt test for OH, blood pressure monitoring, deep breathing and ECG for HRV and general heart health, as well as plasma catecholamine measurements. In general, PD patients with clinical dysautonomia had considerably reduced $^{123}$I-MIBG accumulation and increased washout rates, whereas those not exhibiting autonomic abnormalities had mixed $^{123}$I-MIBG results. For example, one study found 27.4% loss of $^{123}$I-MIBG uptake in nondysautonomia PD patients compared to 50.8% loss in dysautonomia PD [182]. Moreover, H/M was reduced by similar amounts in PD patients with OH at H&Y stage 1 and 2-4 compared to controls, 42.4% and 40.9%, respectively [189]. Yet those without OH have greater H/M loss at H&Y 2-4 (27.1%) than at H&Y 1 (21.7%) compared to controls. Interestingly, it has been reported that PD patients without OH and with normal circadian patterns in blood pressure (nocturnal drop of at least 10% from diurnal) also had significantly low H/M ratios [6], and patients deemed asymptomatic for autonomic failure (AF) as determined by patient reports, had abnormal autonomic function detected by study tests and reduced H/M ratios [181].

$^{123}$I-MIBG has also been used to analyze cardiac innervation in PD patients with genetic mutations. LRRK2 G2019S or R1441G PD carriers have been reported to have decreased $^{123}$I-MIBG uptake compared to controls, although they have higher H/M ratios compared to idiopathic PD. Few of them have autonomic impairments [126, 190]. In two PD Parkin carriers $^{123}$I-MIBG uptake was reported to be within normal range (Figure 3). This matched postmortem results of normal TH positive epicardial nerve fascicles and no evidence of Lewy body pathology [191].

$^{123/125}$I-MIBG use in preclinical studies: $^{123/125}$I-MIBG uptake has been studied in rodents treated with STZ, reserpine, MPTP and 6-OHDA. Notably, many of the preclinical studies using smaller species conducted ex vivo autoradiographic studies after an injection of MIBG to live animals; few performed in vivo $^{123}$I-MIBG SPECT [85, 107, 192] (Table 4). Ex
Table 4. Mapping cardiac innervation in animal models of cardiac sympathetic neurodegeneration

<table>
<thead>
<tr>
<th>Reference</th>
<th>Specie</th>
<th>Animal Model (dose)</th>
<th>Number of subjects</th>
<th>Time of evaluation after model induction</th>
<th>Homogenous cardiac perfusion (Y/N)</th>
<th>Method of radiotracer analysis (In vivo/ex vivo)</th>
<th>% of LV global uptake reduction</th>
<th>LV regions/ROI analyzed</th>
<th>Region of maximal reduction (% of loss)</th>
<th>Significant loss of plasma catecholamines (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No global results provided</td>
<td>Anterior and inferior walls</td>
<td>Inferior (13.1%; 25.3% compared to anterior wall in STZ)</td>
<td>-</td>
</tr>
<tr>
<td>Kiyono et al., 2001</td>
<td>Rat</td>
<td>STZ (55 mg/kg iv)</td>
<td>7</td>
<td>4 weeks</td>
<td>Y ([125]Tc)MIBI)</td>
<td>ex vivo</td>
<td></td>
<td>Anterior, inferior, lateral, and septal walls</td>
<td>Inferior (no values provided)</td>
<td>-</td>
</tr>
<tr>
<td>Kiyono et al., 2005</td>
<td>Rat</td>
<td>STZ (55 mg/kg iv)</td>
<td>5</td>
<td>4 weeks</td>
<td>-</td>
<td>ex vivo</td>
<td></td>
<td>Anterior, inferior, lateral, and septal walls</td>
<td>Inferior (no values provided)</td>
<td>-</td>
</tr>
<tr>
<td>Kusmic et al., 2008</td>
<td>Mouse</td>
<td>STZ (35 mg/kg x 5 ip)</td>
<td>7</td>
<td>7 months</td>
<td>-</td>
<td>in vivo</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Goethals et al., 2009</td>
<td>Rat</td>
<td>STZ (60 mg/kg iv)</td>
<td>12</td>
<td>8 weeks</td>
<td>-</td>
<td>in vivo</td>
<td>3.6-8.4%a</td>
<td>Anterior, antero-lateral, inferior, inferoseptal and antero-septal in STZ</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Matsuki et al., 2010</td>
<td>Rat</td>
<td>STZ (65 mg/kg ip)</td>
<td>7</td>
<td>5 weeks</td>
<td>-</td>
<td>ex vivo</td>
<td>26.33%c</td>
<td>Anterior, inferior, lateral, and septal walls</td>
<td>No differences found between regions</td>
<td>-</td>
</tr>
<tr>
<td>Takatsu et al., 2000</td>
<td>Mouse</td>
<td>MPTP (5 mg/kg x 1 sc)</td>
<td>7</td>
<td>1 week</td>
<td>-</td>
<td>ex vivo</td>
<td>40%a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Takatsu et al., 2002</td>
<td>Mouse</td>
<td>MPTP (5 mg/kg x 2 sc)</td>
<td>6</td>
<td>1 week</td>
<td>-</td>
<td>ex vivo</td>
<td>66%a</td>
<td>Antero-septal (9-10% compared to inferoseptal and infrolateral in STZ)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Fukumitsu et al., 2006</td>
<td>Mouse</td>
<td>MPTP (10 mg/kg x 1 ip)</td>
<td>10</td>
<td>1 week</td>
<td>-</td>
<td>ex vivo</td>
<td>73%a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fukumitsu et al., 2009</td>
<td>Mouse</td>
<td>MPTP (10 mg/kg x 4 ip)</td>
<td>10</td>
<td>1 week</td>
<td>-</td>
<td>ex vivo</td>
<td>61.1%a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fukumitsu et al., 2006</td>
<td>Mouse</td>
<td>MPTP (40 mg/kg x 4 ip)</td>
<td>14</td>
<td>1 day</td>
<td>-</td>
<td>ex vivo</td>
<td>71.7%a</td>
<td>-</td>
<td>-</td>
<td>Y (NE)</td>
</tr>
<tr>
<td>Fukumitsu et al., 2002</td>
<td>Mouse</td>
<td>MPTP (40 mg/kg x 4 ip)</td>
<td>14</td>
<td>4 days</td>
<td>-</td>
<td>ex vivo</td>
<td>57.6%a</td>
<td>-</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>Fukumitsu et al., 2009</td>
<td>Mouse</td>
<td>MPTP (40 mg/kg x 4 ip)</td>
<td>14</td>
<td>7 days</td>
<td>-</td>
<td>ex vivo</td>
<td>49.5%a</td>
<td>N</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>Fukumitsu et al., 2006</td>
<td>Mouse</td>
<td>MPTP (40 mg/kg x 4 ip)</td>
<td>14</td>
<td>21 days</td>
<td>-</td>
<td>ex vivo</td>
<td>47.3%a</td>
<td>N</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>Fukumitsu et al., 2009</td>
<td>Mouse</td>
<td>MPTP (40 mg/kg at 7, 14, and 21 days ip)</td>
<td>14</td>
<td>21 days</td>
<td>-</td>
<td>ex vivo</td>
<td>60.3%a</td>
<td>N</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>Sisson et al., 1987</td>
<td>Rat</td>
<td>6-OHDA (100 mg/kg ip)</td>
<td>11</td>
<td>5 days</td>
<td>-</td>
<td>ex vivo</td>
<td>31%a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nomura et al., 2006</td>
<td>Rabbit</td>
<td>Reserpine (2 mg/kg ip)</td>
<td>4</td>
<td>14 days</td>
<td>Y ([13]N)NH3)</td>
<td>ex vivo</td>
<td>18%a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-OHDA (100 mg/kg iv)</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td>90%a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Cardiac nerve imaging in Parkinson’s disease

<table>
<thead>
<tr>
<th><strong>18F-FDA</strong></th>
<th>Goldstein et al., 1990</th>
<th>Dog</th>
<th>Reserpine (3 mg/kg po)</th>
<th>3</th>
<th>Same animals after 2 weeks</th>
<th>24 hours</th>
<th>-</th>
<th>in vivo</th>
<th>No global results provided</th>
<th>Free wall and septal wall</th>
<th>No differences found between regions</th>
<th>Y(NE, DHPG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goldstein et al., 1991</td>
<td>Dog</td>
<td>6-OHDA (50 mg/kg iv)</td>
<td>3</td>
<td>0</td>
<td>3 days</td>
<td>-</td>
<td>in vivo</td>
<td>&gt;95%</td>
<td>-</td>
<td>-</td>
<td>Y (DHPG, DOPAC)</td>
<td></td>
</tr>
<tr>
<td>Goldstein et al., 2003</td>
<td>Monkey</td>
<td>MPTP (4 doses, dose not clear)</td>
<td>1</td>
<td>2</td>
<td>2 weeks</td>
<td>-</td>
<td>in vivo</td>
<td>no loss, 70% increase</td>
<td>-</td>
<td>-</td>
<td>Y (NE, EPI, DHPG, DOPAC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MPTP (4 doses x 2 separated by 2 weeks, dose not clear)</td>
<td>1</td>
<td>6 weeks</td>
<td>-</td>
<td>-</td>
<td>27.5%</td>
<td></td>
<td>-</td>
<td>-</td>
<td>Y (NE, EPI, DHPG, DOPAC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MPTP (4 doses x 2 separated by 2 weeks, dose not clear)</td>
<td>1</td>
<td>2 years</td>
<td>-</td>
<td>-</td>
<td>no loss, 21.9% increase</td>
<td></td>
<td>-</td>
<td>N (only slightly decreased)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6-OHDA (50 mg/kg iv)</td>
<td>3</td>
<td>1 week</td>
<td>-</td>
<td>-</td>
<td>60%</td>
<td></td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **12C-MHED** | Schmid et al., 1999 | Rat | STZ (50 mg/kg ip) | 18 | 15 | 6 months | - | ex vivo | No global results provided | Proximal and distal segments | Distal (33%) | - |
| | STZ (50 mg/kg ip) | 11 | 6 months | 9 months | - | ex vivo | No change | Free wall and septal wall | No change | Free wall and septal evenly decreased (13%) | N |
| Thackeray et al., 2011 | Rat | STZ (45 mg/kg ip) | 4 | 6 | 2 weeks | - | ex vivo | No change | Free wall and septal wall | No change | N (increased 2.5x) | - |
| | STZ (45 mg/kg ip) | 14 | 8 | 8 weeks | - | - | 13% | | - | - | - |
| Nomura et al., 2006 | Rabbit | Reserpine (2 mg/kg ip) | 4 | 4 | 14 days | Y ([123I]NH3) | in vivo | 50.3% | - | - | - |
| | 6-OHDA (100 mg/kg iv) | 4 | | | | | | 90% | - | - | - |
| Raffel et al., 2006 | Rat | 6-OHDA (7 mg/kg ip) | 5 | 5 | 24 hours | - | ex vivo | 28.2% | - | - | - |
| | 6-OHDA (11 mg/kg ip) | 5 | | | | | | 60.1% | - | - | - |
| | 6-OHDA (15 mg/kg ip) | 5 | | | | | | 53.8% | - | - | - |
| | 6-OHDA (22 mg/kg ip) | 5 | | | | | | 72.5% | - | - | - |
| | 6-OHDA (100 mg/kg ip) | 5 | | | | | | 91.9% | - | - | - |
| Joers et al., 2013 | Monkey | 6-OHDA (50 mg/kg iv) | 5 | Same animals at baseline | 1, 4, 10, 14 weeks | - | in vivo | 51.1% | Anterior, inferior, lateral, and septal walls | Inferior (49.5%) | Y (NE, DOPAC) |

Listed percentages describe loss compared to controls (unless otherwise noted) and reported originally in the reference (a) or calculated based on data (b) or numbers (c) graph from the publication. 

**123I-MIBG, 123I-Meta-iodobenzylguanidine; 6-OHDA, 6-hydroxydopamine; DHPG, Dihydroxyphenylglycine; DOPAC, dihydroxyphenylacetic acid; EPI, epinephrine; LDOPA, L-3,4-dihydroxyphenylalanine; LRRK2, leucine rich repeat kinase 2; LV, left ventricle; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NE, norepinephrine; NH3, ammonia; PD, Parkinson’s disease; STZ, streptozotocine.**
vivo measurements of $^{125I}$-MIBG were calculated as the percentage of dose per gram of tissue, whereas the in vivo evaluations were reported as the percentage of injected activity and not the common H/M measurement due to resolution limitations when working with rodents.

In STZ-induced diabetic models global or heterogeneous $^{123/125}$I-MIBG tracer reduction has been documented [85, 89, 192-194]. Rats treated with STZ (55 mg/kg) and evaluated with $^{125I}$-MIBG SPECT 4 weeks later showed a significant decrease of 25.3% in the inferior compared to the anterior wall of the left ventricle [193]. The heterogeneous pattern of loss was not due to a change in the myocardial blood flow, as rats had normal $^{99m}$Tc-MIBI uptake in both regions of the left ventricle. Similar preferential loss in the inferior wall was reported in a follow-up study where STZ rats were observed 4 weeks later. The animals had reduced $^{125I}$-MIBG in the inferior wall and comparable reduction in NET density measured by a desipramine binding assay [194]. In vivo measurements taken at later timepoints after STZ at either 8 weeks or 7 months, showed less global $^{125I}$-MIBG loss in the left ventricle [85, 192]. Although less $^{125I}$-MIBG uptake was observed, high washout rates were found in both studies compared to controls, suggesting decreased $^{125I}$-MIBG reuptake and NET density. However these reports did not include postmortem histological studies to confirm pattern of $^{125I}$-MIBG uptake or NET density. One study had evaluated hearts of STZ-treated mice 6 months after diabetes onset with immunohistochemistry and found globally diminished TH. This study did not compare regions of the left ventricle in the postmortem analysis or conduct $^{123}$I-MIBG imaging [97]. Differences in the in vivo $^{125I}$-MIBG and ex vivo $^{125I}$-MIBG data may not be due to the selected timepoints, but simply to the method of evaluation.

When reserpine (2 mg/kg ip) was administered to rabbits 2 hours before $^{129}$I-MIBG injection, ligand uptake was not significantly affected (18% loss compared to controls) [163]. Yet, reserpine dosing 4 hours before $^{129}$I-MIBG injection significantly reduced tracer uptake up to 6 hours (63% loss; [195]). Similar results were found in reserpinized rats (4 mg/kg; [160]). These findings suggest that analysis of $^{125I}$-MIBG imaging data in reserpine-treated animals should consider the timing of dosing of both compounds, as well as their differential effects on uptake systems (e.g.: reserpine only affects intravesicular uptake, while $^{125I}$-MIBG can accumulate extra- and intra-vesicularly).

MPTP-treated animals, like STZ models, display impairments in cardiac $^{125}$I-MIBG uptake, but at earlier timepoints and with a greater magnitude. Mice administered subcutaneous MPTP at one dose of 5 mg/kg, or two doses of either 5 mg/kg or 50 mg/kg delivered 16 hours apart and evaluated 1 week after final MPTP dose had a dose-dependent reduction in $^{125I}$-MIBG uptake up to approximately 73% [6]. Similar dose-imaging responses were found in mice evaluated for ex vivo radioactivity of $^{125}$I-MIBG 1 week after intraperitoneal delivery of MPTP as a single dose of 10 mg/kg or a series of 4 doses totaling 40 mg/kg [140]. A comparison between reductions of cardiac $^{125I}$-MIBG uptake and a binding assay for NET showed a close relationship after MPTP. Interestingly, postmortem analysis of synaptophysin, TH and NET immunostaining in the hearts of MPTP-treated mice (30 mg/kg ip x 2, 12 hr apart) one week after neurotoxin challenge, showed no difference compared to controls [154] suggesting that MPTP may disrupt cardiac sympathetic function as observed with $^{123/125}$I-MIBG but not necessarily cause neurodegeneration. This is further supported by the finding of increased plasma NE and ex vivo $^{125I}$-MIBG cardiac radioactivity at 4, 7 and 21 days post MPTP compared to 1 day after toxin dosing with plasma NE comparable to baseline levels at 7 and 21 days [149].

6-OHDA dosing also decreases $^{125}$I-MIBG cardiac uptake. Ex vivo examination of cardiac rat tissue showed a 31% decrease in uptake of $^{125I}$-MIBG 5 days after 6-OHDA (100 mg/kg ip) compared to controls [196]. In rabbits dosing of 100 mg/kg iv of 6-OHDA produced a 90% $^{125I}$-MIBG global retention deficit 14 days after neurotoxin [163]; the animals' heart rate and blood pressure showed no differences compared to controls. Regional analysis of $^{125I}$-MIBG cardiac uptake was not performed in reserpine-, MPTP- or 6-OHDA-based models.

$^{99m}$Tc-FBPBAT

The radiotracer $^{99m}$Tc-FBPBAT binds to α(1)/β(1)-adrenoreceptors providing an assessment...
Cardiac nerve imaging in Parkinson’s disease

### Table 5. Comparison of clinical reports evaluating cardiac innervation in PD using 18F-FDA

<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of Patients</th>
<th>Mean PD age (age range)</th>
<th>PD H&amp;Y stage (disease duration yrs)</th>
<th>Methods to evaluate cardiac DYA</th>
<th>PD patient DYA description</th>
<th>Homogenous cardiac perfusion Y/N (radiotracer)</th>
<th>LV regions analyzed</th>
<th>% of LV global uptake reduction</th>
<th>Region of maximal reduction of loss (%)</th>
<th>Significant loss of plasma catecholamines Y/N</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PD</strong></td>
<td>PD</td>
<td>MSA</td>
<td>PSP</td>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldstein et al., 1997</td>
<td>2</td>
<td>9 w/ SNF</td>
<td>4 w/o SNF</td>
<td>No age defined</td>
<td>Stage and disease duration not defined</td>
<td>NE spillover, plasma DHPG, LDOPA, Dopac</td>
<td>n=2 of 2 PD with SNF (No detectable NE spillover)</td>
<td>-</td>
<td>Septal and free wall</td>
<td>Undetectable levels</td>
</tr>
<tr>
<td>Goldstein et al., 2000</td>
<td>29</td>
<td>24</td>
<td>33</td>
<td>70 (No range defined)</td>
<td>Average H&amp;Y 2.4 (disease duration not defined)</td>
<td>OH evaluation after standing, ECG (BP and HR for RR interval), plasma NE spillover, plasma DHPG and LDOPA, valsalva</td>
<td>n=9 of 29 PD with SNF (increased NE spillover), n=20 of 29 without SNF (12 of 20 had abnormal valsalva)</td>
<td>-</td>
<td>Septal wall (free wall not easily identified; Apex and free wall analyzed by visual inspection)</td>
<td>70% (Apex or free wall (no % provided; n=5 of 20 PD without SNF))</td>
</tr>
<tr>
<td>Li et al., 2002</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>60 (No range defined)</td>
<td>H&amp;Y 1-3; average 2.2, (disease duration not defined)</td>
<td>Plasma NE and Epi and valsalva only conducted at T=1</td>
<td>2 timepoints (T1, T2) 1.4 yrs apart, Abnormal valsalva and no OH at T1 or T2.</td>
<td>-</td>
<td>Septal and lateral walls and apex</td>
<td>23% (Loss of lateral (31% loss)</td>
</tr>
<tr>
<td>Singleton et al., 2004</td>
<td>2</td>
<td>-</td>
<td>1</td>
<td>5th decade of life</td>
<td>Stage not defined (1-10)</td>
<td>OH evaluation after standing, plasma NE and Epi, valsalva</td>
<td>n=2 of 2 have abnormal valsalva, n=1 of 2 OH</td>
<td>Y (18N-NH3)</td>
<td>Septal wall</td>
<td>81.6%</td>
</tr>
<tr>
<td>Tipre et al., 2005</td>
<td>26</td>
<td>-</td>
<td>-</td>
<td>12</td>
<td>No mean defined (30-70)</td>
<td>No additional cardiac DYA evaluations</td>
<td>n=26 of 26 PD with OH</td>
<td>Y (18N-NH3)</td>
<td>Septal wall</td>
<td>No global results provided</td>
</tr>
<tr>
<td>Goldstein et al., 2007a</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>T1= not yet diagnosed with PD; T2= Stage not defined</td>
<td>Plasma NE and Epi, valsalva</td>
<td>2 timepoints (T1, T2) 4 yrs apart, Abnormal valsalva and exercise and orthostatic intolerance</td>
<td>Abnormal valsalva but no OH</td>
<td>Y (18N-NH3)</td>
<td>Septal wall</td>
<td>85%</td>
</tr>
<tr>
<td>Goldstein et al., 2007b</td>
<td>1 (LRRK2 T2356I mutation)</td>
<td>-</td>
<td>-</td>
<td>63</td>
<td>No stage defined (10)</td>
<td>OH evaluation after standing, plasma NE and DHPG, LDOPA, valsalva</td>
<td>Abnormal valsalva but no OH</td>
<td>Y (18N-NH3)</td>
<td>Septal wall</td>
<td>Undetectable levels</td>
</tr>
</tbody>
</table>

Listed percentages describe loss of 18F-FDA uptake compared to controls (unless otherwise noted) and reported originally in the reference (1) or calculated based on data (number) or graph from the publication. *compared across timepoints. **N-NH3:** [18F]-ammonium; ***F-FDA, [18F]-FDG:** dopamine; AF: autonomic failure; BF: baroreflex failure; BP: blood pressure; DHPG, Dihydroxyphenylglycine; DOPAC, Dihydroxyphenylacetic acid; DYA, dopamine; Epi, epinephrine; H&Y, Hoehn & Yahr; iPD, idiopathic PD; LDOPA, L-DOPA; MSA, multiple systems atrophy; NE, norepinephrine; OH, orthostatic hypotension; PAF, pure autonomic failure; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; SNF, sympathetic neurocirculatory failure. 

**Comments:**
- T1, 2 of 9 had normal FDA and 7 of 9 had decreased FDA confined to lateral wall or apex. T2, all 9 PD have reduced FDA.
- Patients with triplication of α-synuclein have similar FDA uptake as iPD.
- FDA uptake significantly reduced in septal wall of PD and PAF compared to controls.
- Severely decreased global FDA uptake at both T1 and T2.

Cardiac nerve imaging in Parkinson’s disease

The properties of $^{99m}$Tc-FBPBAT are advantageous for a clinical setting because of its long 6-hour half-life. Uptake of $^{99m}$Tc-FBPBAT is temperature dependent and has shown greater uptake than the other SPECT adrenergic radiotracer, $^{123/125}$I-MIBG. To its disadvantage, this post-synaptic tracer has a rapid plasma clearance and high renal excretion with 40% of urine radioactivity unmetabolized and 50% converted to a metabolite of $^{99m}$Tc-FBPBAT 6 hours after tracer injection. This tracer has been studied in rats [197] and pigs for feasibility and in humans for radiation dose estimation [198]. From these studies, authors suggest that $^{99m}$Tc-FBPBAT binds to myocardium and is mostly taken up by post-synaptic adrenoreceptors. To the best of our knowledge, there are no reports of $^{99m}$Tc-FBPBAT imaging in PD or animal models of cardiac neurodegeneration.

$^{18}$F-FDA

The radioligand $^{18}$F-FDA targets sympathetic nerves by acting as the catecholamine precursor dopamine. It is taken up into sympathetic neurons via NET, where $^{18}$F-FDA is packaged into endogenous neurotransmitter vesicles. NET uptake-1 specificity for $^{18}$F-FDA is 79% relative to uptake-2, and VMAT2 selectivity is 90%, demonstrating $^{18}$F-FDA ability to reflect the uptake and storage of dopamine [199]. $^{18}$F-FDA acts as a catecholamine precursor, thus it is considered to have greater similarity to NE and greater biological relevance than other catecholamine analogue tracers. Yet, as $^{18}$F-FDA is degraded by MAO or COMT, its visualization is time-limited. $^{18}$F-FDA is not commercially available and as other PET radioligands requires cyclotron production. $^{18}$F-FDA has a biological half-life of 90 minutes and additional radiotracers can be used later in the day if multiple tracers need to be evaluated [200]. Cardiac $^{18}$F-FDA PET images are quantified from time-averaged $^{18}$F-FDA concentrations from multiple regions of interest within the left ventricle. Time points for data acquisition and the quantity and location of regions of interest vary across studies.

Clinical application of $^{18}$F-FDA: Similar to $^{123}$I-MIBG, $^{18}$F-FDA uptake is globally reduced in PD patients compared to controls [4, 31, 127, 201-204] and MSA patients [4, 201] (Table 5). Patients with diffuse ventricular loss were significantly older (average 66 years) than those PD with localized loss (57 years) [4]. The localized loss was found in the free wall and apex of the left ventricle compared to the septal wall. $^{13}$N-NH3 perfusion studies confirmed that the regional differences were due to changes in sympathetic function [204]. PD patients exhibiting symptoms of dysautonomia compared to those without sympathetic abnormalities consistently had reduced cardiac $^{18}$F-FDA [4, 31, 201-204]. It should be noted that normal $^{18}$F-FDA uptake was reported in 4 out of 20 PD patients with chronic OH or abnormal respons-
Cardiac nerve imaging in Parkinson’s disease

es to the Valsalva maneuver [4]. Additionally, when cardiac \(^{18}\text{F}\)-FDA uptake was tracked for 1-4 years in PD patients with no signs of dysautonomia, a progressive loss of uptake was observed overtime (Figure 4). The global loss averaged 23\%, while the regional analysis showed a maximal 31\% loss in the free wall and 16\% in the septal wall [203]. These data suggest that sympathetic denervation can occur without clinically measurable symptoms. In that regard, changes in cardiac \(^{18}\text{F}\)-FDA uptake seem to predate the onset of motor dysfunction associated with nigrostriatal dopaminergic loss. In a case report reduced \(^{18}\text{F}\)-FDA plus exercise and orthostatic intolerance was found 4 years before the onset of PD motor symptoms [202].

\(^{18}\text{F}\)-FDA has also been used to assess cardiac sympathetic loss in PD patients with known genetic mutations. A single case of LRRK2 T2356I mutation [31] and 2 patients with triplication of the \(\alpha\)-synuclein gene [127] have shown virtually absent cardiac \(^{18}\text{F}\)-FDA uptake. This suggests severe cardiac sympathetic loss. The 3 patients had abnormal Valsalva response, although only 1 triplication case exhibited OH; the 3 of them had normal levels of circulating NE.

\(^{18}\text{F}\)-FDA use in preclinical studies: \(^{18}\text{F}\)-FDA PET has been used for evaluation of cardiac sympathetic loss induced by reserpine, 6-OHDA and MPTP intoxication in dogs and nonhuman primates (Table 4). Dogs treated with reserpine (3 mg/kg po) 24 hours before \(^{18}\text{F}\)-FDA PET imaging, showed decreased \(^{18}\text{F}\)-FDA retention at 30 minutes and accelerated \(^{18}\text{F}\)-FDA clearance compared to untreated animals [205]. Authors proposed that reserpine did not inhibit \(^{18}\text{F}\)-FDA initial uptake, and in the axoplasm it was quickly metabolized to \(^{18}\text{F}\)-DOPAC and then released into the blood stream. In a follow up study, dogs injected with 6-OHDA (total dose of 50 mg/kg iv) and imaged with \(^{18}\text{F}\)-FDA at least 3 days later had a decrease of more than 95\% in cardiac uptake [166], suggesting \(^{18}\text{F}\)-FDA uptake was limited due to the destruction of the sympathetic terminals. The cardiac radioactivity clearance was similar to that in reserpine-treated dogs.

In nonhuman primates, \(^{18}\text{F}\)-FDA imaging [152] was used to compare a single 6-OHDA-treated rhesus monkey (total dose 50 mg/kg) to 1 monkey that received a series of 4 MPTP doses (actual doses were not specified) and did not show motor PD signs (acute phase; \(n=1\)) to another animal that had a series of 8 doses to induce severe parkinsonism (subacute phase; \(n=1\)) within 2 and 6 weeks, respectively. The 6-OHDA treated monkey imaged 1 week post-toxin showed decreased global cardiac \(^{18}\text{F}\)-FDA concentration. Plasma catecholamines (NE and epinephrine) and metabolites (DHPG and DOPAC) were markedly lower in this monkey than untreated animals. Approximately 6 weeks after the last MPTP dose the monkey in acute phase had increased cardiac \(^{18}\text{F}\)-FDA concentrations by 70\% compared to controls, and decreased rate of \(^{18}\text{F}\)-FDA loss as compared with the accelerated \(^{18}\text{F}\)-FDA loss and overall 60\% reduction in \(^{18}\text{F}\)-FDA uptake in the 6-OHDA-treated monkey. However, the acute MPTP treatment decreased circulating catecholamines compared to untreated monkeys, and the values were comparable to subacute phase and 6-OHDA monkeys. The subacute MPTP monkey had decreases of heart \(^{18}\text{F}\)-FDA radioactivity levels of 27.5\%, but not as low as the 6-OHDA-treated monkey. When 3 other MPTP-treated monkeys (undefined toxin doses) were evaluated 2 years after intoxication, both \(^{18}\text{F}\)-FDA radioactivity and plasma catecholamines returned to values similar to untreated animals suggesting spontaneous recovery. Cardiac regional uptake of \(^{18}\text{F}\)-FDA was not evaluated in the monkey or dog models.

\(^{11}\text{C}\)-MHED

The radioligand \(^{11}\text{C}\)-MHED acts as a false neurotransmitter that binds to NET and is packaged into neurotransmitter vesicles [206]. An advantage of \(^{11}\text{C}\)-MHED compared to \(^{123}\text{I}\)-MIBG and \(^{18}\text{F}\)-FDA, is its higher specificity to neuronal uptake-1 mechanisms (92\%). \(^{11}\text{C}\)-MHED also has greater metabolic stability than \(^{18}\text{F}\)-FDA due to its resistance to MAO and COMT metabolism [207]. For these reasons, \(^{11}\text{C}\)-MHED more accurately measures the integrity of sympathetic noradrenergic nerves [176, 208]. \(^{11}\text{C}\)-MHED has a myocardial half-life of 240 minutes in humans [209]. Clinical studies with \(^{11}\text{C}\)-MHED PET usually use the uptake index calculated as the \(^{11}\text{C}\)-MHED uptake during the final frame (30-40 minutes) divided by the integral of blood time-activity at 40 minutes [210, 211] or an irreversible model to derive the influx of \(^{11}\text{C}\)-MHED with an ROI in the center of the left
ventricle chamber as an input function. These methods of analysis have limitations as \(^{11}\)C-MHED retention index depends on the re-uptake by NET. \(^{11}\)C-MHED is quickly taken up by NET and released through diffusion for re-uptake into the neurons; therefore, these methods are limited by the rate of diffusion out of the neuron and do not reflect the true amount of NET. Others have suggested that \(^{11}\)C-MHED PET data may be best analyzed using a reversible model [168, 212, 213]. Clinical MHED regional analysis of the left ventricle has commonly evaluated the perfusion areas the left circumflex artery (LCX), left anterior descending artery (LAD) and right coronary artery (RCA). LAD, LCX and RCA distributions overlap segments of the anterior, inferior, lateral or septal walls of the left ventricle (Figure 5).

**Clinical application of \(^{11}\)C-MHED:** There have been only few reports evaluating cardiac innervation in PD with \(^{11}\)C-MHED [214-216]. In these reports the PD population varied within the first stages of the disease (reported as H&Y 1-2.5 stages or duration years) (Table 6). In these studies, global cardiac denervation was present in 44 to 85% of PD patients (Figure 6). The global loss varied between studies from 23-36% [214], 26% [161] to 50% [216]. A clear association between loss of cardiac \(^{11}\)C-MHED uptake and disease duration, mean age or H&Y stage was not found.

In 2 of the 3 studies \(^{11}\)C-MHED uptake was reported as the number of abnormal sectors in polar maps representing the LAD, LCX and RCA perfusion areas [161, 216]. These studies categorize the patients by the extent of their global denervation into normal, mild to moderate and severe denervation. The LCX perfusion area was the most affected, with the number of abnormal sectors reaching up to 100% [161] and 70.9% [216]. One of the studies further compared regional \(^{11}\)C-MHED uptake in the apex and the anterior, septal, inferior and lateral walls of the left ventricle in proximal and distal segments. The most severe denervation was found in the proximal lateral and inferior walls (loss of 74% and 69%, respectively [216]). Presence of OH symptoms was only assessed in one of the 3 studies, without finding a correlation [214]. The other 2 studies [161, 216] also assessed striatal dihydrotetrabenazine ([\(^{11}\)C]DTBZ), a radioligand that binds to vesicular monoamine transporter (VMAT2) and reflects nigral dopaminergic neuron activity. The investigators found no correlation between sympathetic nigrostriatal and cardiac loss.

\(^{11}\)C-MHED use in preclinical studies: \(^{11}\)C-MHED PET has been used to image cardiac sympathetic innervation in rats, rabbits and monkeys after STZ, reserpine or 6-OHDA-intoxication (Table 4).

Two studies in STZ-induced diabetic rats evaluated \(^{11}\)C-MHED uptake [90, 217] at different timepoints. In the first study, diabetic rats (50 mg/kg ip STZ) were assessed with \(^{11}\)C-MHED...
Table 6. Comparison of clinical reports evaluating cardiac innervation in PD using $^{11}$C-MHED

<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of Patients</th>
<th>Mean PD age (age range)</th>
<th>PD H&amp;Y stage (disease duration yrs)</th>
<th>Methods to evaluate cardiac DYA</th>
<th>PD patient DYA description</th>
<th>Homogeneous cardiac perfusion Y/N (radio-tracer)</th>
<th>LV regions analyzed</th>
<th>% of LV global uptake reduction</th>
<th>Region of maximal reduction (% of abnormal sectors - AS)</th>
<th>Significant loss of plasma catecholamines Y/N</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{11}$C-MHED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Berding et al., 2003</td>
<td>5</td>
<td>2</td>
<td>-</td>
<td>No mean defined (51-69)</td>
<td>No stage defined (2-16)</td>
<td>OH evaluation with Schellong test</td>
<td>n=3 of 5 PD with OH, n=2 of 5 probable/possible PD without OH</td>
<td>Polar maps created for global MHED influx values.</td>
<td>23.8-36.4%$^a$</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Raffel et al., 2006</td>
<td>9</td>
<td>10</td>
<td>8</td>
<td>No mean defined (35-77)</td>
<td>H&amp;Y 1.5-2.5 (disease duration not defined)</td>
<td>No additional cardiac DYA evaluations</td>
<td>n=1 of 9 PD with OH</td>
<td>LCX, LAD, and RCA. Polar maps with 480 sectors created. Regional effects are calculated as % of 480 sectors that are abnormal.</td>
<td>26%$^a$ (96%$^a$ of 480 sectors have abnormal values)</td>
<td>LCX and RCA (100% AS)</td>
<td>-</td>
</tr>
<tr>
<td>Wong et al., 2012</td>
<td>27</td>
<td>-</td>
<td>33</td>
<td>62 (50-74)</td>
<td>H&amp;Y 1-2.5 (1-14)</td>
<td>No additional cardiac DYA evaluations</td>
<td>No further description included</td>
<td>LCX, LAD, and RCA. Anterior, inferior, lateral and septal walls in respect to proximal and distal areas. Polar maps with 480 sectors created. Regional effects calculated as % of 480 sectors that are abnormal.</td>
<td>50%$^a$ (61.7%$^a$ of 480 sectors have abnormal values)</td>
<td>Lateral (distal 68%$^a$ AS and proximal 74%$^a$ AS); Inferior (distal 63% AS and proximal 69% AS); LCX (70.9%$^a$ AS)</td>
<td>-</td>
</tr>
</tbody>
</table>

Listed percentages describe loss of $^{18}$F-FDA uptake compared to controls (unless otherwise noted) and reported originally in the reference ($^*$) or calculated based on data ($^*$ numbers or $^c$ graph) from the publication. $^c$compared to MSA group. $^{11}$C-MHED, $^{11}$C-meta-hydroxyephedrine; AS, abnormal sectors; DYA, dysautonomia; H&Y, Hoehn & Yahr; LAD, left anterior descending artery; LCX, left circumflex artery; LV, left ventricle; MSA, multiple systems atrophy; NE, norepinephrine; OH, orthostatic hypotension; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; RCA, right coronary artery.
PET at 6 and 9 months [90]. At 6 months, proximal left ventricular segments were not significantly different (9% loss) compared to controls, yet distal segments were significantly decreased (33%). At 9 months, proximal and distal regions were significantly decreased (44% and 40%, respectively). However, NE quantification by HPLC showed no significant difference in either proximal or distal segments at 6 or 9 months in STZ rats compared to controls. In the second study, diabetic rats (45 mg/kg ip STZ) also showed $^{11}$C-MHED uptake reduction throughout the entire heart (13–26%) and equal loss (13%) in the septum and free wall of the left ventricle compared to controls at 8 but not at 2 weeks after hyperglycemic induction [217]. However, at 8 weeks postmortem cardiac TH staining was similar to controls. Plasma and left ventricle NE were increased by 2.5 times and 1.2 times, respectively, compared to controls, suggesting normalization of cardiac sympathetic innervation. The $^{11}$C-MHED uptake data suggests that STZ takes over 2 weeks to produce cardiac neurodegeneration, lasting up to 9 months. Since different regions were analyzed between studies a pattern of STZ-induced loss is difficult to identify. Additionally, the postmortem data did not confirm sympathetic nerve loss, and instead suggest a dysfunctional cardiac sympathetic system.

$^{11}$C-MHED PET has also been used to evaluate cardiac innervation after 6-OHDA intoxication in rats [215], rabbits [163] and monkeys [152, 168]. In rats, $^{11}$C-MHED PET performed 24 hours after varying doses of 6-OHDA (7, 11, 15, 22 and 100 mg/kg ip) [215] showed a dose-dependent decrease in radioligand uptake, with the highest dose creating an average whole-heart $^{11}$C-MHED reduction of 92%. Middle-range doses induced variable loss of $^{11}$C-MHED uptake, yet it was highly correlated with NET density as determined postmortem (30 minutes after $^{11}$C-MHED injection) with a 3H-mazindol saturation binding assay. In 6-OHDA-treated rabbits (100 mg/kg iv), $^{11}$C-MHED PET 2 weeks post intoxication showed a 90% reduced cardiac uptake com-
Cardiac nerve imaging in Parkinson’s disease

pared to controls. This loss was greater than the one induced by 2 mg/kg ip reserpine (50.3%; [163]). Rhesus monkeys given 6-OHDA (50 mg/kg iv) had significantly lower $^{11}$C-MHED distribution values at 1, 4, 10 and 14 weeks than at baseline, with some recovery that stabilized between 10 and 14 weeks (Figure 7). At 14 weeks, there was a 51% global reduction of $^{11}$C-MHED uptake [168] and regional analysis showed a maximal loss in the inferior wall of the left ventricle (49.5%) compared to the anterior wall. Circulating catecholamines and their metabolites were also reduced and positively correlated with $^{11}$C-MHED uptake. Postmortem quantification of cardiac TH and PGP9.5 immunoreactivity confirmed sympathetic cardiac loss [218].

Conclusions and future steps

The impact of cardiac neurodegeneration and dysautonomia in PD disability cannot be underestimated. The symptoms of fatigue, OH, shortness of breath and changes in cardiac electrical activity complicate typical PD motor symptoms, are part of the nonmotor symptom spectrum and should be considered when planning a patient treatment strategy. Advances in molecular imaging have allowed progress in the identification and characterization of cardiac sympathetic innervation, its role in dysautonomia in PD, and the evaluation of animal models, yet much work is still needed.

Molecular imaging using $^{123/125}$I-MIBG, $^{18}$F-FDA or $^{11}$C-MHED has demonstrated that PD patients have loss of cardiac sympathetic innervation. This has proven useful as a tool for differential diagnosis between PD and MSA or PSP, as the two latter diseases may present with similar symptoms, but unlike PD, they usually have normal cardiac postganglionic sympathetic uptake. Interestingly, the amount and distribution of sympathetic loss in PD seems to

Figure 7. Horizontal long axis view of the heart shows $^{11}$C-MHED uptake at baseline (A) and 10 weeks after systemic 6-OHDA (B) in a rhesus monkey. Polar maps display $^{11}$C-MHED distribution volume in left ventricle with the greatest deficit in the apex and inferior walls 10 weeks after toxin (D) compared to baseline (C). A, anterior; I, inferior; L, lateral; S, septal.
Cardiac nerve imaging in Parkinson’s disease

vary among individuals and it has been report-
ed as either diffuse, at times extensively, or fol-
lowing a nonuniform pattern with maximal loss
in the apex and the inferior and lateral walls of
the left ventricle. Progression of the neurode-
generation overtime seems to influence the
depth and extension of the sympathetic loss.
For example, 9 PD patients with H&Y stages
ranging from 1-3 showed after 2 years a 31%
reduction in $^{11}$C-MHED uptake in the left ven-
tricular free wall and 16% in the septum while a
more uniform loss is seen in advanced stages
of the disease [203]. This suggests that regional
quantification may be more sensitive than
global data to evaluate progression and, poten-
tially, recovery. An obstacle against drawing a
final conclusion on patterns of loss in PD is that
only few studies, with small number of cases
each, reported regional analysis of cardiac sympa-
thetic innervation. Increased efforts towards regional mapping are needed to help
characterize a universal PD pattern of sympa-
thetic cardiac loss.

The use of sympathetic radiotracers has estab-
lished that PD patients exhibiting autonomic
symptoms such as OH have some degree of
cardiac sympathetic neurodegeneration. Yet at
this time, based on the accumulated evidence
predicting extent of nerve loss based on symp-
toms alone is unreliable. First, depending on
the radioligand, reports may be based on a few
patients, and although they provide valuable
data to strengthen the importance of cardiac
neurodegeneration in PD, the scope of the con-
clusions that can be drawn from them is limited
[201, 202]. Second, the definition of autonomic
dysfunction and failure used as the criteria for
including patients in different groups varies
between articles. For example, some patients
were considered to have autonomic failure by
assessment of OH abnormalities [203, 204] while
others defined it by sympathetic neurocircu-
tulary failure or the presence of both OH and
blood pressure defects [201]. Third, evaluation of
dysautonomia symptoms, like head tilt, OH
after standing, ECG for variation in RR intervals,
plasma catecholamines and Valsalva, vary
between reports or is missing. Further research
is needed to assess the measurements predic-
tive value, sensitivity and specificity toward
specific disorders. Although overall autonomic
scoring systems exist, including Composite
Autonomic Symptom Score (COMPASS) and
Autonomic Symptom Profile (ASP), these scales
have limited evaluation of cardiac dysautonom-
ia, and are questionnaire-based, restricting
their physiological relevance [219-221]. The
development of a composite rating scale evalu-
ating multiple cardiac autonomic measure-
ments with levels of severity and PD H&Y stage
that can be correlated with imaging measures
may be sensitive enough to estimate cardiac
neurodegeneration, yet this scale does not cur-
rently exist.

Identification of clusters of patients with gene
mutations associated to PD, yet asymptomatic,
present an opportunity to study prodromal signs
including cardiac dysfunction and may allow
to answer the question if dysautonomia pre-
ces motor symptoms or not. Imaging of car-
diac sympathetic denervation with different
radiotracers has shown varying levels of loss in
cases of PD with LRRK2 G2019S, R1441G and
T2356I mutations and triplication of α-synu-
clerin. Further research needs to be conducted
to better understand cardiac dysautonomia and
denervation in PD linked to genetics.

Preclinical evaluation with molecular imaging
presents advantages for clinical translation as
the outcome measure and analysis can be eas-
ily transferred between species. In that regard,
studies in animal models allow, for example,
the isolation of specific conditions in order to
identify the magnitude of their impact in the
overall health, as well as time-dependent cor-
relations with actual biochemical and morpho-
dological data. During the evaluation of current
available models of cardiac neurodegeneration
in PD some emerged as better suited for pre-
clinical testing, STZ seems to have several limi-
tations for modeling cardiac sympathetic neu-
rodegeneration. $^{125}$I-MIBG studies suggest that
STZ induces inconsistent lesions that also vary
depending on the timeline of STZ administra-
tion, while $^{11}$C-MHED studies demonstrate a
reduction in tracer uptake, but it does not
match the biochemical analyses. Overall, STZ-
induced neuronal death does not result as
quickly as some of the other toxin based mod-
els and produces hyperglycemia, a confound-
ing factor for PD research, and should be con-
sidered when selecting appropriate models.
MPTP-based models do not seem to induce
long-term cardiac sympathetic denervation, but
instead develop cardiac dysfunction that recov-
ers overtime, making it a poor system to study
the full cardiac effects found in PD. Additionally,
subacute MPTP dosing to monkeys, which produces cardiac abnormalities, is associated with severe parkinsonism that requires extensive animal care and increased measures of personnel safety, making it a difficult model to use. In comparison systemic 6-OHDA-based models seem to be more reliable with less human risk. In that regard the 6-OHDA monkey model has a lesion that is stabilized between 2-3 months, with a reproducible pattern of loss where the left ventricular inferior wall retains a significant deficit compared to the inferior wall, similar to PD. In addition, 6-OHDA also induces a reduction in plasma NE as often found in PD patients with other dysautonomia symptoms and when medications are restricted. Genetic models have begun to be evaluated for cardiac pathologies and hold potential to unravel the etiologies of cardiac dysautonomia. Thy1-αSyn mice have already shown α-synuclein accumulation and cardiac autonomic dysregulation. Studies to evaluate the relationship between protein accumulation and cardiac innervation in Thy1-αsyn mice as well as evaluation of transgenic animals with other PD related mutations such as with LRRK2 are warranted as they can help identify and test targets for neuroprotective strategies.

The concept of cardiac imaging as a biomarker for disease progression has already been tested to monitor reduction of cardiac ¹⁸F-FDA uptake after 4-years. A natural follow up to this study would be to assess the effects of disease-modifying strategies, once one is identified. A challenge for neuroprotective studies is defining the time to begin treatment for cardiac neurodegeneration that would increase the chances for success. Ideally, it would be when there are enough cardiac ganglia neurons to protect and/or to stimulate reinnervation. Identification of subtle neuronal loss, as well as evaluation of neuroprotective therapies, requires methods that enable researchers to interpret changes overtime. ¹¹C-MHED PET imaging has demonstrated sympathetic nerve restoration in heart transplant patients [55] by defining a reinnervation threshold based on the ¹¹C-MHED uptake/min. Since then, spatial resolution has increased in PET technologies. Although advances in SPECT imaging are expected to improve quantification of the images, the spatial resolution is still too poor to detect what we expect would be slow and small changes in reinnervation following treatment in PD. At this time it is not possible to distinguish epicardial versus endocardial layers of the heart with molecular imaging. Progress to improve the use of these techniques may assist the differentiation of PD from other parkinsonian disorders or identify disease progression. Further development in sympathoneuronal radiotracers may also strengthen the management of cardiac neurodegeneration and guidance for future therapies. In addition a more comprehensive assessment where presynaptic and postsynaptic imaging is combined may give clinicians a better understanding to the cardiac deficits and better predict outcomes. Equally important will be the development and application of radioligands aiming to visualize candidate neurodegenerative pathways (e.g.: α-synuclein, inflammation).

To conclude, molecular imaging is an effective tool to detect cardiac sympathetic neurodegeneration in PD and animal models and holds promise as a tool to detect disease progression and treatment efficacy. With the advancement of these technologies, molecular imaging may better identify patterns of cardiac sympathetic loss and correlate with clinical cardiac dysautonomia features.

Acknowledgements

This project was supported in part by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021; WNPRI NIH base grant P51RR000167 and Awards from the Graduate School, University of Wisconsin, Madison. The authors are grateful to Dr. Jim Holden for his comments and Mr. Shahrose Rahman for computer graphics. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosure of conflict of interest

The authors declare no conflict of interest.

Address correspondence to: Dr. Marina E Emborg, Preclinical Parkinson’s Research Program, Wisconsin National Primate Research Center, University of Wisconsin, Madison, 1220 Capitol Court, Madison, WI 53715. Tel: 608-262-9714; Fax: 608-263-3524; E-mail: emborg@primate.wisc.edu (MEE); vjoers@primate.wisc.edu (VJ)
Cardiac nerve imaging in Parkinson’s disease

References

Cardiac nerve imaging in Parkinson’s disease


[57] Goldstein DS, Holmes CS, Dendi R, Bruce SR and Li ST. Orthostatic hypotension from sym-
Cardiac nerve imaging in Parkinson’s disease


Brouha L, Cannon WB and Dill DB. The heart rate of the sympathectomized dog in rest and exercise. J Physiol 1936; 87: 345-359.


[105] Pop-Busui R. What do we know and we do not know about cardiovascular autonomic neurop-


[116] Pinon M, Racotta IS, Ortiz-Butron R and Ra


[118] Weiner N, Cloutier G, Bjur R and Pfeffer RI. Modification of norepinephrine synthesis in intact tissue by drugs and during short-term ad-


Cardiac nerve imaging in Parkinson’s disease


[138] Fuller RW and Hemrick-Luecke SK. Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mimicked by 1-methyl-4-phenylpyridinium (MPP+) and not blocked by deprenyl. Life Sci 1986; 39: 1645-1650.


Cardiac nerve imaging in Parkinson’s disease


[158] Porter CC, Totaro JA and Burcin A. The relationship between radioactivity and norepinephrine concentrations in the brains and hearts of mice following administration of labeled methyldopa or 6-hydroxydopamine. J Pharmacol Exp Ther 1965; 150: 17-22.

[159] Porter CC, Totaro JA and Stone CA. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J Pharmacol Exp Ther 1963; 140: 308-316.


Cardiac nerve imaging in Parkinson’s disease


[195] Matsunami I, Bunko H, Taki J, Nakajima K, Muramori A, Kuji I, Miyachi T, Tonami N and Hisa-
Cardiac nerve imaging in Parkinson’s disease


[215] Raffel DM, Chen W, Sherman PS, Gildersleeve DL and Jung YW. Dependence of cardiac 11C-meta-hydroxyephedrine retention on norepi-
Cardiac nerve imaging in Parkinson’s disease


